Latanoprost Stulln

Latanoprost, the active ingredient in Latanoprost Stulln, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It reduces intra‑ocular pressure by enhancing uveoscleral outflow, making it a cornerstone therapy for patients with primary open‑angle glaucoma and ocular hypertension.

GNH USA supplies Latanoprost Stulln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards, offering batch‑to‑batch traceability and supporting regulatory compliance for importers across multiple regions.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma and ocular hypertension.

- Primary open-angle glaucoma: reduces intra‑ocular pressure and helps prevent optic nerve damage. - Ocular hypertension: lowers eye pressure to reduce the risk of progression to glaucoma. - Secondary open-angle glaucoma: provides pressure reduction similar to primary disease. - Pseudoexfoliative glaucoma: achieves intra‑ocular pressure control in this subtype. - Post‑laser trabeculoplasty management: maintains lowered pressure after laser procedures.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation or burning sensation upon instillation. - Increased eyelash growth (hypertrichosis). - Darkening of the iris (gradual pigmentation change). - Blurred vision: transient visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Ocular inflammation (uveitis or iritis). - Macular edema: swelling of the central retina. - Severe allergic reaction: swelling, itching, or rash. - Persistent eye pain or discomfort. - Sudden loss of vision. - Corneal ulceration or infection.

Before initiating therapy, evaluate ocular health and monitor intra‑ocular pressure regularly. - Assess corneal health: avoid use in patients with active corneal disease. - Screen for ocular infections: do not use during active bacterial or viral eye infections. - Caution in patients with a history of uveitis: monitor for inflammation. - Advise patients to avoid contact lens wear for at least 15 minutes after instillation. - Store at room temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Latanoprost may interact with other ocular or systemic agents that affect intra‑ocular pressure or ocular surface.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: additive iris pigmentation and eyelash changes. - Combination with ocular corticosteroids: increased risk of cataract formation.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: may enhance systemic absorption leading to cardiovascular effects. - Carbonic anhydrase inhibitor eye drops: additive pressure‑lowering effect, monitor for hypotony. - Systemic non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce prostaglandin efficacy. - Anticholinergic agents: potential for reduced tear production, monitor ocular surface comfort.